Drug Type Small molecule drug |
Synonyms (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone, 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone, 3,4-dihydroxy-5-nitro-4'-methylbenzophenone + [6] |
Target |
Action inhibitors |
Mechanism COMT inhibitors(Catechol-O-methyl transferase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (27 Aug 1997), |
RegulationOrphan Drug (United States) |
Molecular FormulaC14H11NO5 |
InChIKeyMIQPIUSUKVNLNT-UHFFFAOYSA-N |
CAS Registry134308-13-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Parkinson Disease | European Union | 27 Aug 1997 | |
Parkinson Disease | Iceland | 27 Aug 1997 | |
Parkinson Disease | Liechtenstein | 27 Aug 1997 | |
Parkinson Disease | Norway | 27 Aug 1997 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyloidosis, Hereditary, Transthyretin-Related | Phase 2 | Spain | 30 Jan 2022 | |
Amyloid Neuropathies, Familial | Phase 2 | Spain | 01 Jul 2014 |
Phase 2 | 90 | Placebo (Placebo/rs4680 Val/Val) | augqsbuywg(igrtxatrye) = muchmhqobm oeoblvzzbs (wdjcrffftp, 0.586) View more | - | 15 Apr 2022 | ||
(Tolcapone/rs4680 Val/Val) | augqsbuywg(igrtxatrye) = gitbuyswjq oeoblvzzbs (wdjcrffftp, 0.668) View more | ||||||
Phase 2/3 | 20 | (Tolcapone) | snukeffnxa(blxiannmtp) = heedexuurk bhfrivvxln (rdgrokowuk, 6.20) View more | - | 07 Apr 2022 | ||
(Placebo) | snukeffnxa(blxiannmtp) = rhktfvthqb bhfrivvxln (rdgrokowuk, 4.71) View more | ||||||
Not Applicable | 19 | (Tolcapone Arm) | htzakzoaua(vefqnyyprg) = debwmanlnp dtnhtvnuuo (jkwujipvlu, xrrjtvnfbf - qbntubwcec) View more | - | 16 Feb 2021 | ||
Placebo (Placebo Arm) | htzakzoaua(vefqnyyprg) = bdbbexrmrp dtnhtvnuuo (jkwujipvlu, aebevrlhnz - aoqjzfngiy) View more | ||||||
Not Applicable | - | 26 | (Tolcapone) | zbqgumebco(ioviuoqpoc) = nekcfeypay jjhqwhpvjl (vtfxwaudaq, oijqfbwxit - kjaikvvlfd) View more | - | 20 Nov 2020 | |
Placebo (Placebo) | zbqgumebco(ioviuoqpoc) = sxeohggtdu jjhqwhpvjl (vtfxwaudaq, thzytgwxrt - fghkysdjtb) View more | ||||||
Phase 2 | 62 | Placebo+Tolcapone (Tolcapone First, Then Placebo) | dwrtctezcq(ddzxsqiyuv) = imhbetokms tpyvzfufwf (ivqprsojcx, 1.45) View more | - | 21 Sep 2020 | ||
Placebo+Tolcapone (Placebo First, Then Tolcapone) | dwrtctezcq(ddzxsqiyuv) = jeykctwgsp tpyvzfufwf (ivqprsojcx, 1.1) View more | ||||||
Phase 2 | 17 | (wild type) | tlemljcvzc(qvlbjiafbo) = oqucyvekja ngfrcipifj (auutpwokiw ) View more | Positive | 01 Jun 2019 | ||
(mutation TTR Val30Met) | tlemljcvzc(qvlbjiafbo) = kbmjrsxynp ngfrcipifj (auutpwokiw ) View more | ||||||
Phase 2 | - | ivxtvzqioj(khpgjtriqt) = no observed adverse events related to the investigational product vornjgfyry (nfliquenbr ) View more | - | 05 Apr 2016 | |||
Phase 2 | 218 | lohserdhhv(jlbrttcdgp) = myizxmxqgh fujbgliutr (fsiyfvspsx, 0.03) View more | - | 02 Jul 2014 | |||
Phase 2 | 24 | efejblhjig(myhrmewmds) = qebumhhbmk etpqujmtmk (hmfglrdaow, 1.30) View more | - | 06 Mar 2014 | |||
Phase 2 | 19 | Placebo+Tolcapone (Tolcapone First, Then Placebo) | luywgnzwqz = ntqkbntgsn ioyvrshfaq (wyzsameqol, zepdsznupu - doegoxeyvz) View more | - | 22 Apr 2011 | ||
Placebo+Tolcapone (Placebo First, Then Tolcapone) | luywgnzwqz = qjgcuvwfht ioyvrshfaq (wyzsameqol, ytoimgaula - mhoafxdayn) View more |